{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:49:53Z","timestamp":1787759393246,"version":"build-2784847793"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006436","name":"Silpakorn University","doi-asserted-by":"publisher","award":["RG 003\/2567"],"award-info":[{"award-number":["RG 003\/2567"]}],"id":[{"id":"10.13039\/501100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p><jats:italic>Pseudomonas aeruginosa<\/jats:italic> associated with hospital-acquired infection is often resistant to various antibiotics and is associated with high mortality worldwide. The appropriate treatment of <jats:italic>Pseudomonas aeruginosa<\/jats:italic> resistant to carbapenems but susceptible to traditional antipseudomonal non-carbapenem \u03b2-lactam agents (Car-R\/NonCar-S <jats:italic>P<\/jats:italic>. <jats:italic>aeruginosa<\/jats:italic>) remains unclear. This retrospective study evaluated risk factors for 14-day and 30-day mortality among treatment regimens against Car-R\/NonCar-S <jats:italic>P<\/jats:italic>. <jats:italic>aeruginosa<\/jats:italic>. This study enrolled 180 patients with Car-R\/NonCar-S <jats:italic>P<\/jats:italic>. <jats:italic>aeruginosa<\/jats:italic> infection at Phramongkutklao Hospital between January 2019 and December 2023. The 14-day and 30-day mortality rates were 18.3% and 28.9%, respectively. Bloodstream infection (OR 1.97, 95% CI 0.88\u20134.43), septic shock (OR 3.3, 95% CI 1.30\u20138.40), Acute Physiology and Chronic Health Evaluation (APACHE) II &lt; 14 (OR 0.13, 95% CI 0.03\u20130.54), Sequential Organ Failure Assessment (SOFA) &lt;7 (OR 0.25, 95% CI 0.11\u20130.56), and Pitt bacteremia score &lt;4 (OR 0.16, 95% CI 0.05\u20130.47) were associated with 14-day mortality. There was a higher 14-day and 30-day mortality in patients treated with piperacillin\/tazobactam or aminoglycosides but there was no significant difference among antipseudomonal antimicrobial agents in the treatment of Car-R\/NonCar-S <jats:italic>P<\/jats:italic>. <jats:italic>aeruginosa<\/jats:italic> infection. We supported the use of traditional antipseudomonal \u03b2-lactam agents to treat Car-R\/NonCar-S <jats:italic>P<\/jats:italic>. <jats:italic>aeruginosa<\/jats:italic> infections, however the use of piperacillin\/tazobactam might be concerned in some cases and further investigations were needed.<\/jats:p>","DOI":"10.1371\/journal.pone.0313944","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T18:30:21Z","timestamp":1732041021000},"page":"e0313944","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem \u03b2-lactam agents"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6963-9245","authenticated-orcid":true,"given":"Suvadee","family":"Supreeyasakon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jantima","family":"Traipattanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5265-5808","authenticated-orcid":true,"given":"Jatapat","family":"Hemapanpairoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piraporn","family":"Juntanawiwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9974-957X","authenticated-orcid":true,"given":"Wichai","family":"Santimaleeworagun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"issue":"4","key":"pone.0313944.ref001","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1556\/030.66.2019.036","article-title":"Characterization of carbapenem-resistant but cephalosporin-susceptible Pseudomonas aeruginosa","volume":"66","author":"Y Khalili","year":"2019","journal-title":"Acta Microbiol Immunol Hung"},{"key":"pone.0313944.ref002","author":"H Sati","journal-title":"WHO Bacterial Priority Pathogens List, 20242024."},{"key":"pone.0313944.ref003","doi-asserted-by":"crossref","first-page":"1298858","DOI":"10.3389\/fmicb.2023.1298858","article-title":"WHO AWaRe classification for antibiotic stewardship: tackling antimicrobial resistance\u2014a descriptive study from an English NHS Foundation Trust prior to and during the COVID-19 pandemic.","volume":"14","author":"R Abdelsalam Elshenawy","year":"2023","journal-title":"Front Microbiol."},{"issue":"1","key":"pone.0313944.ref004","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01243-16","article-title":"Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure","volume":"61","author":"DJ Buehrle","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0313944.ref005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijid.2019.05.004","article-title":"Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend","volume":"85","author":"A Balkhair","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pone.0313944.ref006","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jmii.2014.01.005","article-title":"Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections","volume":"49","author":"KY Lin","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"issue":"4","key":"pone.0313944.ref007","doi-asserted-by":"crossref","first-page":"dlab187","DOI":"10.1093\/jacamr\/dlab187","article-title":"Mortality in patients with carbapenem-resistant Pseudomonas aeruginosa with and without susceptibility to traditional antipseudomonal \u03b2-lactams.","volume":"3","author":"J Howard-Anderson","year":"2021","journal-title":"JAC Antimicrob Resist."},{"key":"pone.0313944.ref008","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2147\/IDR.S358778","article-title":"Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes.","volume":"15","author":"J Qin","year":"2022","journal-title":"Infect Drug Resist."},{"issue":"1","key":"pone.0313944.ref009","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1186\/s12879-022-07436-w","article-title":"Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study.","volume":"22","author":"A Vivo","year":"2022","journal-title":"BMC Infectious Diseases"},{"issue":"Pt 12","key":"pone.0313944.ref010","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1099\/jmm.0.073262-0","article-title":"Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome","volume":"63","author":"RC Dantas","year":"2014","journal-title":"J Med Microbiol"},{"issue":"2","key":"pone.0313944.ref011","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.diagmicrobio.2014.07.003","article-title":"Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome","volume":"80","author":"SJ Jeong","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"pone.0313944.ref012","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9020514","article-title":"Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: What Is the Influence of XDR Phenotype on Outcomes?","volume":"9","author":"MM Montero","year":"2020","journal-title":"J Clin Med."},{"key":"pone.0313944.ref013","author":"National Antimicrobial Resistant Surveillance Center","journal-title":"Antimocrobial Resistance 2000\u20132022 Thailand"},{"issue":"5","key":"pone.0313944.ref014","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/femsre\/fux020","article-title":"Structure, function and regulation of Pseudomonas aeruginosa porins","volume":"41","author":"S Chevalier","year":"2017","journal-title":"FEMS Microbiol Rev"},{"issue":"3","key":"pone.0313944.ref015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/1348-0421.12021","article-title":"Molecular investigation of carbapenem resistance among multidrug-resistant Pseudomonas aeruginosa isolated clinically in Thailand","volume":"57","author":"P Khuntayaporn","year":"2013","journal-title":"Microbiol Immunol"},{"issue":"1","key":"pone.0313944.ref016","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bjid.2016.10.008","article-title":"Carbapenem-resistant and cephalosporin-susceptible: a worrisome phenotype among Pseudomonas aeruginosa clinical isolates in Brazil.","volume":"21","author":"EH Campana","year":"2017","journal-title":"Braz J Infect Dis"},{"issue":"3","key":"pone.0313944.ref017","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.diagmicrobio.2013.11.014","article-title":"Mechanisms of carbapenem resistance in cephalosporin-susceptible Pseudomonas aeruginosa in China","volume":"78","author":"ZR Zeng","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"pone.0313944.ref018","article-title":"Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections","author":"PD Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pone.0313944.ref019","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/10600280231201953","article-title":"Treatment Outcomes for Carbapenem-Resistant and Cephalosporin-Susceptible Pseudomonas aeruginosa Pneumonia","volume":"58","author":"TH Ng","year":"2024","journal-title":"Ann Pharmacother"},{"key":"pone.0313944.ref020","year":"2022","journal-title":"CDC\/NHSN Surveillance Definitions for Specific Types of Infections"},{"key":"pone.0313944.ref021","author":"The Clinical & Laboratory Standards Institute (CLSI).","journal-title":"CLSI Standards: Guidelines for Health Care Excellence"},{"key":"pone.0313944.ref022","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.ijid.2009.11.019","article-title":"Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection","volume":"14","author":"C Su\u00e1rez","year":"2010","journal-title":"International Journal of Infectious Diseases"},{"issue":"7","key":"pone.0313944.ref023","first-page":"428","article-title":"Risk factors for the failure of treatment of Pseudomonas aeruginosa bacteremia in critically ill patients","volume":"72","author":"S Yoshida","year":"2017","journal-title":"Pharmazie"},{"issue":"1","key":"pone.0313944.ref024","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clinthera.2022.12.004","article-title":"Piperacillin\/Tazobactam Dose Optimization in the Setting of Piperacillin\/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.","volume":"45","author":"CM Gill","year":"2023","journal-title":"Clin Ther."},{"key":"pone.0313944.ref025","volume-title":"CLSI supplement M100","author":"Clinical and Laboratory Standards Institute (CLSI).","year":"2023","edition":"33"},{"issue":"8","key":"pone.0313944.ref026","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1128\/AAC.00521-12","article-title":"Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections","volume":"56","author":"TW Felton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"pone.0313944.ref027","doi-asserted-by":"crossref","first-page":"O831","DOI":"10.1111\/1469-0691.12677","article-title":"In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae","volume":"20","author":"Y Harada","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"pone.0313944.ref028","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02874-20","article-title":"Antimicrobial Susceptibility Profiles To Predict the Presence of Carbapenemase Genes among Carbapenem-Resistant Pseudomonas aeruginosa Isolates","volume":"59","author":"S Vallabhaneni","year":"2021","journal-title":"J Clin Microbiol"},{"key":"pone.0313944.ref029","year":"2022","journal-title":"CLSI. Piperacillin-Tazobactam Breakpoints for Enterobacterales. 1st ed. CLSI rational document MR14. Clinical and Laboratory Standards Institute"},{"key":"pone.0313944.ref030","author":"R. Humphries","journal-title":"AST News Update June 2023: New! CLSI M100-Ed33: Updated Aminoglycoside Breakpoints for Enterobacterales and Pseudomonas aeruginosa 2023"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T18:30:29Z","timestamp":1732041029000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313944"}},"subtitle":[],"editor":[{"given":"Iddya","family":"Karunasagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0313944","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]}}}